Hugh is an accomplished biotech executive with over 22 years of experience in drug development for global markets, pharmaceutical commercialization, international business development and partnering, general management and profit accountability experience. Hugh’s current focus is the founding CEO of Kinoxis Therapeutics Pty Ltd, a new company formed at the beginning of 2018 as spin out from the University of Sydney to develop a range of novel therapeutics for the treatment of substance use disorders and other central nervous system disorders.
More recently, Hugh has been CEO of Hatchtech Pty Ltd, an Australian company developing a novel technology for the control of invertebrate pests. The Company’s lead product is Xeglyze™ Lotion, a next generation prescription head lice product in development that aims to overcome the frustrating, costly and inconvenient cycles of retreatment for head lice infestation currently experienced by children and their parents. In 2015, the company signed a multi-country commercialization agreement for Xeglyze™ with integrated pharmaceutical company Dr. Reddy’s Laboratories (NYSE: RDY). Xeglyze™ has completed clinical development, and a New Drug Application has been filed with the US Food and Drug Administration (FDA).
Hugh has worked in executive positions for a wide spectrum of pharmaceutical and biotechnology companies, including Acrux Limited, Phosphagencis Ltd, Sigma Pharmaceuticals, Mayne Pharma, and Faulding Pharmaceuticals. Whilst at Acrux, Hugh was Director Business Development when in 2010, the company licensed their testosterone product Axiron to Eli Lilly for AUD$335 million in milestones plus royalties.
Hugh has a Bachelor of Science (Honors) in Chemistry from the University of Melbourne and an MBA from the Melbourne Business School.